Cytokinetics, Inc.
Cytokinetics Announces Positive Primary Results for Aficamten in Obstructive HCM
Summary
On May 13, 2024, Cytokinetics, Incorporated announced the primary results from the SEQUOIA-HCM Phase 3 clinical trial, demonstrating that aficamten significantly improved exercise capacity and symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) compared to placebo. The results, presented at the European Society of Cardiology Heart Failure 2024 Congress and published in the New England Journal of Medicine, showed statistically significant and clinically meaningful improvements in all secondary endpoints and were consistent across all prespecified subgroups. The treatment was well-tolerated with no treatment interruptions due to low left ventricular ejection fraction (LVEF). The company is preparing for regulatory submissions for aficamten, following these positive results.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement